In class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma - Supplementary Material

Supplementary Figure S1. Study design and timelines
Supplementary Figure S2. Populations for the IRd and V-based cohorts Selected from US MM-6 and INSIGHT MM.
Supplementary Table S1. Patient baseline and disease characteristics before IPTW.
Supplementary Table S2. Duration of treatment with individual agents in the IRd and V-based IPTW-weighted cohorts.
Supplementary Table S3. Stem cell transplant and subsequent PI therapy in the V-based IPTW-weighted cohort.